Interestingly, the antihuman CD115 Ab, emactuzumab, decreased the number of CD163+ CD206+ M2 macrophages in patients with melanoma by depleting immature TAMs before the IL-4 stimulation phase (57). Here, CD163 is linked to melanoma.